Table 4.
In Vitro Antimicrobial Susceptibility of Bloodstream Isolates by Site of Acquisition.
| Antimicrobial agent/combination | Community-acquired (n = 161) | Health care–associated (n = 159) | Hospital-acquired (n = 70) |
|---|---|---|---|
| Ampicillin | 63 (39) | 47 (30) | 17 (24) |
| Ampicillin-sulbactam | 112/160 (70) | 99/158 (63) | 46 (66) |
| Cefazolin | 128/160 (80) | 112 (70) | 47 (67) |
| Ceftriaxone | 151 (94) | 139 (87) | 58/69 (84) |
| Cefepime | 156 (97) | 152 (96) | 66 (96) |
| Piperacillin-tazobactam | 157/159 (99) | 151/157 (96) | 65/69 (94) |
| Ertapenem | 157 (98) | 149 (94) | 64 (91) |
| Meropenem | 161 (100) | 158 (99) | 68 (97) |
| Ciprofloxacin | 134 (83) | 123/158 (78) | 60/68 (88) |
| Gentamicin | 147/158 (93) | 148/158 (94) | 63/69 (91) |
| Trimethoprim-sulfamethoxazole | 126/160 (79) | 119/159 (75) | 53 (76) |
| Cefepime + gentamicin | 157 (98) | 155/159 (97) | 67/69 (97) |
| Cefepime + ciprofloxacin | 158 (98) | 152 (96) | 66/69 (96) |
| Piperacillin-tazobactam + gentamicin | 159 (99) | 155/158 (98) | 67 (96) |
| Piperacillin-tazobactam + ciprofloxacin | 159/160 (99) | 152/158 (96) | 66/69 (96) |
| Meropenem + gentamicin | 161 (100) | 159 (100) | 69 (99) |
| Meropenem + ciprofloxacin | 161 (100) | 158 (99) | 69/69 (100) |
Note. Data show number of susceptible isolates (%) or number of susceptible/number of tested isolates (%), if not all isolates were tested.